1. Generics Bulletin
  2. >>Business
  3. >>Deals

Ipca Adds To API Business By Acquiring Ramdev

 
• By Penelope MacRae

India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.

DigitalGraph
Ipca’s deal will expand its API business and help it target global markets • Source: Shutterstock

India’s Ipca Laboratories has announced its third acquisition in two years with a deal to buy manufacturer Ramdev Chemical Ltd for INR1.1bn ($15.7mn). Ipca said the acquisition would allow the company to “grow its active pharmaceutical ingredient (API) business by adding new molecules in its products basket, with the possibility of forward-integrating such products in its dosage formulations business for the world market.”

Ipca will purchase 100% of shares in Ramdev, which is based in the Palghar district of the western Indian state...

Welcome to Generics Bulletin

Create an account to read this article

Already a subscriber?

More from Deals

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By Dave Wallace

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

Irish Ruling Gives Go-Ahead For Endo-Mallinckrodt Merger

 
• By Dave Wallace

A ruling from Ireland’s High Court has cleared the way for Endo and Mallinckrodt to consummate their merger in early August.

Adalvo Changes Hands As EQT Takes Control

 
• By Dave Wallace

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By Dave Wallace

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

More from Business

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 
• By Anju Ghangurde

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

Adalvo Changes Hands As EQT Takes Control

 
• By Dave Wallace

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By Dave Wallace

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.